DDInter1702 DDInter1627
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Sorafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rufinamide
Sorafenib {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Primidone
Primidone {u} (Compound) treats {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} (Compound) binds {v} (Gene) SCN2A
SCN2A {u} (Gene) is bound by {v} (Compound) Rufinamide
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Primidone
Primidone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rufinamide
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Primidone
Primidone {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Sorafenib {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) is associated with {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Sorafenib {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is associated with {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Rufinamide
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Phenytoin {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Rufinamide
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rufinamide (Compound)
Sorafenib (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Rufinamide (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) treats epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) binds SCN2A (Gene) and SCN2A (Gene) is bound by Rufinamide (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rufinamide (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Rufinamide (Compound)
Sorafenib (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is associated with epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Sorafenib (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is associated with epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Rufinamide (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Rufinamide (Compound)